Taysha Gene Therapies
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle in...
Latest News
4 days ago · seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call TranscriptTaysha Gene Therapies, Inc. ( TSHA ) Q3 2026 Earnings Call November 12, 2026 8:30 AM EST Company Participants Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Kamran Alam - CFO & Corporate Secretary Fred Porter - Chief of Staff & Technical Operations Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Elizabeth Webster - Goldman Sachs Group, Inc., Research Division Biren Amin - Piper Sandler & Co., Research Division Wesley Yon - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Presentation Operator Thank you for standing by, and welcome to Taysha Gene Therapies Third Quarter 2026 Financial Results Conference Call.
4 days ago · marketbeat.com
Taysha Gene Therapies Q3 Earnings Call HighlightsTaysha Gene Therapies NASDAQ: TSHA expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half of 2027, executives said on the company's third-quarter earnings call.
4 days ago · globenewswire.com
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateREVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027
12 days ago · globenewswire.com
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2026, and host a corporate update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com.
2 months ago · globenewswire.com
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual MeetingDALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada, from October 14 – 17, 2026. The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting.
2 months ago · seekingalpha.com
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest ApprovalTaysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivotal data collection and manufacturing scale-up without immediate dependence on accelerated regulatory filing. TSHA-102's early data show deepening, durable functional gains in Rett patients, but pivotal efficacy, safety, and manufacturing qualification remain key investment inflection points.
3 months ago · seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call TranscriptTaysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
3 months ago · marketbeat.com
Taysha Gene Therapies Q2 Earnings Call HighlightsTaysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.
3 months ago · globenewswire.com
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateCompleted dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027
5 months ago · seekingalpha.com
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label PotentialTaysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pivotal trial progress. TSHA-102 achieved 100% response rate at 12 months in Part A, surpassing the 33% response threshold needed for regulatory submission. Alignment with the FDA on pivotal trial endpoints and interim analysis could enable an accelerated BLA submission in 1H 2027.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TSHA